Flezurafenib

Flezurafenib
Clinical data
Other names	JZP-815
Identifiers
	IUPAC name 5-[[(3S)-3-[5-(4-fluorophenyl)-1H-imidazol-2-yl]-3,4-dihydro-2H-chromen-6-yl]oxy]-3,4-dihydro-1H-1,8-naphthyridin-2-one;
CAS Number	2760321-00-2;
PubChem CID	162772363;
IUPHAR/BPS	13233;
UNII	P26TTM6U27;
Chemical and physical data
Formula	C26H21FN4O3
Molar mass	456.477 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC(=O)NC2=NC=CC(=C21)OC3=CC4=C(C=C3)OC[C@@H](C4)C5=NC=C(N5)C6=CC=C(C=C6)F;
	InChI InChI=InChI=1S/C26H21FN4O3/c27-18-3-1-15(2-4-18)21-13-29-25(30-21)17-11-16-12-19(5-7-22(16)33-14-17)34-23-9-10-28-26-20(23)6-8-24(32)31-26/h1-5,7,9-10,12-13,17H,6,8,11,14H2,(H,29,30)(H,28,31,32)/t17-/m1/s1; Key:TWJSMWXWCWQPRO-QGZVFWFLSA-N;

Flezurafenib is an investigational new drug designed as a rapidly accelerated fibrosarcoma (RAF) kinase inhibitor which is being evaluated for the treatment of cancer. Developed by Jazz Pharmaceuticals, this novel therapeutic agent is currently being explored for its efficacy against solid tumors and hematological malignancies harboring oncogenic mutations that activate the RAS-RAF-MAPK signaling pathway.^[1]^[2] As of January 2025, flezurafenib has reached Phase 1 clinical trials, where it is being evaluated for the treatment of advanced cancers and advanced malignant solid neoplasms.^[1]

References

^ ^a ^b "JZP-815". PatSnap.
^ Riaud M, Maxwell J, Soria-Bretones I, Dankner M, Li M, Rose AA (February 2024). "The role of CRAF in cancer progression: from molecular mechanisms to precision therapies". Nature Reviews. Cancer. 24 (2): 105–122. doi:10.1038/s41568-023-00650-x. PMID 38195917.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[PatSnap-1] "JZP-815". PatSnap.

[Riaud_2024-2] Riaud M, Maxwell J, Soria-Bretones I, Dankner M, Li M, Rose AA (February 2024). "The role of CRAF in cancer progression: from molecular mechanisms to precision therapies". Nature Reviews. Cancer. 24 (2): 105–122. doi:10.1038/s41568-023-00650-x. PMID 38195917.

[1]